Spyre Therapeutics, Inc.
SYRE
Rang in aandelen
#2304
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Aandeelprijs
$93.11
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$8.59B
Verandering (1 dag)
1.87%
Verandering (1 jaar)
319.23%
Land
US
Handel Spyre Therapeutics, Inc. (SYRE)
Categorie
Healthcare
Omzet van Spyre Therapeutics, Inc. (SYRE)
Omzet in Jun 2026 TTM: $90.49M
Volgens de laatste financiële rapporten van Spyre Therapeutics, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $90.49M. In 2023 behaalde het bedrijf een omzet van $886.00K een daling ten opzichte van de omzet in het jaar 2022, die $2.33M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Spyre Therapeutics, Inc. van 2014 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $90.49M | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $886.00K | -61.96% |
| 2022 | $2.33M | -87.57% |
| 2021 | $18.74M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $3.89M | -25.30% |
| 2017 | $5.21M | 12.47% |
| 2016 | $4.63M | -23.94% |
| 2015 | $6.09M | 0.00% |
| 2014 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 13,850.43% |
US
|
|
| $2.23B | 2,362.04% |
US
|
|
| $15.74B | 17,298.20% |
AU
|
|
| $6.02B | 6,553.80% |
NL
|
|
| - | - |
CH
|
